OBJECTIVE: To observe whether there is constitutive activation of nuclear transcription factor kappaB (NF-kappaB) and its effect on proliferation and apoptosis of human gastric cancer cell lines. METHODS: Nuclear/cytoplasmic protein expression of NF-kappaB was analyzed by Western blot in four different gastric cancer cell lines. Trans AM(TM) NF-kappaB p65 Kit was used for detecting the difference of p65 activity. The effect of PDTC (pyrrolidine dithiocarbamate), a specific inhibitor of NF-kappaB on the proliferation of gastric cancer cells, was measured by MTT (3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide) method. The apoptotic rates of AGS and SGC-7901 gastric cancer cell lines were measured with flow cytometer (FCM) after treatment by PDTC. RESULTS: The constitutive activations of NF-kappaB were identified in four gastric cancer cell lines. The expression of activated subunit of p50 was lower in AGS cell line, and higher in MKN28, MKN45 and SGC-7901 cell lines. The expression of activated subunit of p65 was lower in MKN28 and MKN45 cell lines, and higher in AGS and SGC-7901 cell lines. Both the activity of NF-kappaB and the cell proliferation were significantly inhibited in experimental group treated by PDTC, compared with control groups (p<0.01). An increased apoptotic rate and a decreased proliferating activity were observed after the gastric cancer cells were exposed to PDTC for 24 h. CONCLUSIONS: These results suggested that the constitutive activation and the protein expression of NF-kappaB are different in gastric cancer cell lines. PDTC can inhibit NF-kappaB activity and cell proliferation, which related to an increased cell apoptosis. The results disclosed that NF-kappaB could be a potential therapeutic target for solid tumor therapy. Copyright (c) 2005 S. Karger AG, Basel.
OBJECTIVE: To observe whether there is constitutive activation of nuclear transcription factor kappaB (NF-kappaB) and its effect on proliferation and apoptosis of humangastric cancer cell lines. METHODS: Nuclear/cytoplasmic protein expression of NF-kappaB was analyzed by Western blot in four different gastric cancer cell lines. Trans AM(TM) NF-kappaB p65 Kit was used for detecting the difference of p65 activity. The effect of PDTC (pyrrolidine dithiocarbamate), a specific inhibitor of NF-kappaB on the proliferation of gastric cancer cells, was measured by MTT (3-[4,5-dimethythiazol-2-yl]-2,5-diphenyltetrazolium bromide) method. The apoptotic rates of AGS and SGC-7901 gastric cancer cell lines were measured with flow cytometer (FCM) after treatment by PDTC. RESULTS: The constitutive activations of NF-kappaB were identified in four gastric cancer cell lines. The expression of activated subunit of p50 was lower in AGS cell line, and higher in MKN28, MKN45 and SGC-7901 cell lines. The expression of activated subunit of p65 was lower in MKN28 and MKN45 cell lines, and higher in AGS and SGC-7901 cell lines. Both the activity of NF-kappaB and the cell proliferation were significantly inhibited in experimental group treated by PDTC, compared with control groups (p<0.01). An increased apoptotic rate and a decreased proliferating activity were observed after the gastric cancer cells were exposed to PDTC for 24 h. CONCLUSIONS: These results suggested that the constitutive activation and the protein expression of NF-kappaB are different in gastric cancer cell lines. PDTC can inhibit NF-kappaB activity and cell proliferation, which related to an increased cell apoptosis. The results disclosed that NF-kappaB could be a potential therapeutic target for solid tumor therapy. Copyright (c) 2005 S. Karger AG, Basel.